Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
IPO Year: 2018
Exchange: NASDAQ
Website: ymabs.com
Recent Analyst Ratings for Y-mAbs Therapeutics Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | $23.00 | Outperform | Oppenheimer |
| 8/16/2024 | $20.00 | Overweight | Cantor Fitzgerald |
| 6/28/2024 | $21.00 | Buy | Truist |
| 5/10/2023 | $5.00 → $13.00 | Neutral → Outperform | Wedbush |
| 4/3/2023 | Buy → Neutral | Guggenheim | |
| 1/27/2023 | $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/5/2023 | Outperform → Market Perform | Cowen | |
| 12/2/2022 | $23.00 → $5.00 | Buy → Neutral | BofA Securities |
| 12/2/2022 | Buy → Neutral | BofA Securities | |
| 10/31/2022 | $6.00 | Outperform → Neutral | Wedbush |
Y-mAbs Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory high-risk neuroblastoma in the journal Nature Communications. The article, titled "The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Life Sciences Conference on Tuesday, February 11, 2025 at 4:40 p.m. ET. A live webcast will be available under the Events section of the Company's investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and American College of Nuclear Medicine (ACNM) Annual Meeting being held on January 30 to February 1, 2025 in Anaheim, California. The poster titled "Preclinical and Translational Pharmacokinetics of
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025 Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, within Full Year 2024 top line guidance range Company reports preliminary estimated unaudited cash, cash equivalents and marketable securities of approximately $67 million as of Decem
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025 Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, within Full Year 2024 top line guidance range Company reports preliminary estimated unaudited cash, cash equivalents and marketable securities of approximately $67 million as of De
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 5:15 p.m. PT. A live webcast will be available under the Events section of the Company's investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30
Clear Street Launches Healthcare & Biotechnology Equity Research
Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives
Y-mAbs Therapeutics Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target
Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00
Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target
Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00
Truist initiated coverage on Y-mAbs Therapeutics with a new price target
Truist initiated coverage of Y-mAbs Therapeutics with a rating of Buy and set a new price target of $21.00
Y-mAbs Therapeutics upgraded by Wedbush with a new price target
Wedbush upgraded Y-mAbs Therapeutics from Neutral to Outperform and set a new price target of $13.00 from $5.00 previously
Y-mAbs Therapeutics downgraded by Guggenheim
Guggenheim downgraded Y-mAbs Therapeutics from Buy to Neutral
Y-mAbs Therapeutics downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded Y-mAbs Therapeutics from Equal-Weight to Underweight and set a new price target of $4.00
Y-mAbs Therapeutics downgraded by Cowen
Cowen downgraded Y-mAbs Therapeutics from Outperform to Market Perform
Y-mAbs Therapeutics downgraded by BofA Securities with a new price target
BofA Securities downgraded Y-mAbs Therapeutics from Buy to Neutral and set a new price target of $5.00 from $23.00 previously
Y-mAbs Therapeutics downgraded by BofA Securities
BofA Securities downgraded Y-mAbs Therapeutics from Buy to Neutral
Y-mAbs Therapeutics downgraded by Wedbush with a new price target
Wedbush downgraded Y-mAbs Therapeutics from Outperform to Neutral and set a new price target of $6.00
Y-mAbs Therapeutics Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wedell-Wedellsborg Johan bought $890,411 worth of shares (127,549 units at $6.98) (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wg Biotech Aps bought $309,477 worth of shares (51,837 units at $5.97), increasing direct ownership by 1% to 4,425,229 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wedell-Wedellsborg Johan bought $309,477 worth of shares (51,837 units at $5.97) (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wedell-Wedellsborg Johan bought $521,294 worth of shares (93,187 units at $5.59) (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Wg Biotech Aps bought $521,294 worth of shares (93,187 units at $5.59), increasing direct ownership by 2% to 4,373,392 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Y-mAbs Therapeutics Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
PRESIDENT & CEO Rossi Michael J sold $20,368 worth of shares (3,917 units at $5.20), decreasing direct ownership by 3% to 137,083 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
CHIEF BUSINESS OFFICER Gad Thomas sold $56,536 worth of shares (10,810 units at $5.23), decreasing direct ownership by 5% to 202,721 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
CFO and Treasurer Pfreundschuh Peter P. was granted 31,800 shares, increasing direct ownership by 69% to 77,800 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
CHIEF BUSINESS OFFICER Gad Thomas was granted 32,000 shares, increasing direct ownership by 18% to 213,531 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SVP & CHIEF OPERATING OFFICER Wilms Joris was granted 21,500 shares, increasing direct ownership by 70% to 52,100 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
PRESIDENT & CEO Rossi Michael J was granted 105,300 shares, increasing direct ownership by 295% to 141,000 units (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SVP, General Counsel & Secry Larocca John was granted 21,500 shares (SEC Form 4)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SEC Form 3 filed by new insider Gentilcore Douglas J
3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SEC Form 3 filed by new insider Larocca John
3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Y-mAbs Therapeutics Inc. SEC Filings
SEC Form 144 filed by Y-mAbs Therapeutics Inc.
144 - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc.
424B5 - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
SEC Form S-8 filed by Y-mAbs Therapeutics Inc.
S-8 - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
SEC Form 10-K filed by Y-mAbs Therapeutics Inc.
10-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
SEC Form 10-Q filed by Y-mAbs Therapeutics Inc.
10-Q - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
Y-mAbs Therapeutics Inc. FDA approvals
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC
Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:
Y-mAbs Therapeutics Inc. Leadership Updates
Live Leadership Updates
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial Officer role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, aft
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Mary Tagliaferri, M.D. to the Company's Board of Directors, effective February 29, 2024. Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors. "We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs," said
Y-mAbs Therapeutics Inc. Financials
Live finance-specific insights
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):Investors (international):(877) 407-0792(201) 689-8263 To access a live webcast of the update,
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increaseContinued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong KongPart A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran Norman LaFrance, M.D. as Chief Development Officer Cash and cash equivalents of $77.8 million held as of June 30, 2024, reflects $0.8 million cash burn in the six months ended June 30, 2024;
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):(877) 407-0792Investors (international):(201) 689-8263 To access a live webcast of the update, please use this
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumesCash and cash equivalents of $75.7 million as of March 31, 2024, and cash burn of only $2.9 million for the quarter ended March 31, 2024 Management reiterates full year 2024 financial guidance and anticipated cash runway into 2027The Company will host a conference call on Wednesday, May 8, 2024, at 8:00 a.m. ET NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NA
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Wednesday, May 8, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Bo Kruse, Chief Financial Officer; and Thomas Gad, Founder, Vice Chair and Chief Business Officer. C
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December 31, 2023; Reiterate anticipated cash runway into 2027Management announces full year 2024 financial guidance The Company will host a conference call on Friday, March 1, 2024, at 8:00 a.m. ET NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, t
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 1, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Thomas Gad, Founder, Vice Chair and Chief Bu
Y-mAbs Therapeutics Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SEC Form SC 13G filed by Y-mAbs Therapeutics Inc.
SC 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc. (Amendment)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc. (Amendment)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc. (Amendment)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc. (Amendment)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc. (Amendment)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SEC Form SC 13G filed by Y-mAbs Therapeutics Inc.
SC 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)